Statement of Changes in Beneficial Ownership (4)
May 20 2021 - 4:19PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Nusbickel Thomas |
2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc.
[
CRMD
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP, Chief Commercial Officer |
(Last)
(First)
(Middle)
C/O CORMEDIX INC. 300 CONNELL DRIVE,, SUITE 4200 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/13/2021 |
(Street)
BERKELEY HEIGHTS,, NJ 07922
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy Common Stock) | $7.56 | 5/13/2021 | | A | | 260000 | | (1) | 5/13/2031 | Common Stock | 260000 | $0 | 260000 | D | |
Stock Option (Right to Buy Common Stock) | $7.56 | 5/13/2021 | | A | | 7500 | | (2) | 5/13/2031 | Common Stock | 7500 | $0 | 7500 | D | |
Explanation of Responses: |
(1) | The options vest as follows: 160,000 will vest over four years in four (4) equal installments on the first four anniversaries of May 13, 2021. The remaining 100,000 options vest on the achievement of certain milestones, subject to continued employment. |
(2) | These options were granted on May 13, 2021. These options shall vest in full on the first anniversary of the grant date, subject to continued employment. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Nusbickel Thomas C/O CORMEDIX INC. 300 CONNELL DRIVE, SUITE 4200 BERKELEY HEIGHTS,, NJ 07922 |
|
| EVP, Chief Commercial Officer |
|
Signatures
|
/s/ Thomas Nusbickel | | 5/20/2021 |
**Signature of Reporting Person | Date |
CorMedix (NASDAQ:CRMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
CorMedix (NASDAQ:CRMD)
Historical Stock Chart
From Apr 2023 to Apr 2024